Study Assesses Epidemiology of Carbapenem-resistant Enterobacteriaceae
the ONA take:
Most carbapenem-resistant enterobacteriacecae (CRE) cases in the United States are associated with a high prevalence of prior hospitalizations or indwelling devices and discharge to long-term care settings, a study published in JAMA has shown.
Because CRE cases have been increasingly reported worldwide as a cause of infection with high-mortality rates, researchers sought to determine the population-based CRE incidence in seven US geographical areas.
For the study, researchers analyzed case records from persons living in 1 of 7 US metropolitan areas in Colorado, Georgia, Maryland, Minnesota, New Mexico, New York, and Oregon.
Results showed that the incidence of CRE was 2.93 per 100,000 people. Researchers also found that the majority of CRE cases were in women.
CRE cases were significantly higher than predicted for Georgia, Maryland, and New York, while Colorado, New Mexico, and Oregon had significantly fewer cases than predicted.
The study demonstrated that most CRE cases occurred in patients with prior hospitalizations or indwelling devices, and the majority of admitted cases results in discharge to a long-term care setting.
The carbapenem antibiotic class includes imipenem, meropenem, doripenem, and ertapenem. Extended-spectrum cephalosporin-resistant enterobacteriaceae are typically susceptible to carbapenems except ertapenem.
Most carbapenem-resistant enterobacteriacecae (CRE) cases associated with a high prevalence of prior hospitalizations.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|